ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1431

Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study

Alojzija Hocevar1, Katja Perdan Pirkmajer1, Matija Tomsic1 and Ziga Rotar1, 1University Medical Center Ljubljana, LJUBLJANA, Slovenia

Meeting: ACR Convergence 2020

Keywords: ANCA associated vasculitis, interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Vasculitis – ANCA-Associated Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Recently, an association between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) has been uncovered. We aimed to determine the rate of ILD in our AAV patient cohort and to compare clinical characteristics of AAV patients with and without associated ILD.

Methods: We analysed medical records of prospectively diagnosed and followed AAV patients at our secondary/tertiary rheumatology centre between January 2010 and May 2020. The diagnosis of ILD was based on lung HRCT findings.

Results: During the observation period, we identified 102 incipient AAV patients (50 had granulomatosis with polyangiitis, and 52 microscopic polyangiitis). Thirteen (12.7%) patients had ILD (ILD-AAV group). 12/13 had usual interstitial pneumonia (UIP) pattern and 1/13 non-specific fibrosis on HRCT. ILD was diagnosed in tandem with AAV in 9/13 patients, and 9 months to 5 years prior to AAV in 4/17 patients. Characteristics of ILD-AAV, and non-ILD-AAV groups are presented in Table 1. ILD-AAV patients more commonly reported of weight loss, less frequently had ENT involvement, and were predominantly a-MPO ANCA positive (92.3%). Follow up data were available for 90 AAV patients (88.2%; 13 ILD-AAV and 77 non-ILD-AAV). During the median (IQR) follow up of 30.6 (11.4; 62.8) months, 5/13 (38.5%) ILD-AAV patients died, compared to 7 (9.1%) deaths registered in non-ILD-AAV group. The crude mortality rate evaluated by Cox proportional hazards regression was significantly higher for AAV-ILD group (HR 5.5 (95%CI 1.7-17.3), p=0.004).

Conclusion: In our incipient AAV cohort 13% of patients presented with ILD. The AAV patients with ILD had a higher mortality rate than the rest of the cohort.

Table 1. Clinical characteristics of ILD-AAV and non-ILD-AAV group


Disclosure: A. Hocevar, None; K. Perdan Pirkmajer, None; M. Tomsic, None; Z. Rotar, None.

To cite this abstract in AMA style:

Hocevar A, Perdan Pirkmajer K, Tomsic M, Rotar Z. Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/interstitial-lung-disease-in-patients-with-anca-associated-vasculitis-a-prospective-single-centre-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-lung-disease-in-patients-with-anca-associated-vasculitis-a-prospective-single-centre-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology